Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data

Mauricio Tohen Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, USACorrespondence: Mauricio TohenDepartment of Psychiatry and Behavioral Sciences, University of New Mexico, 2400 Tucker Ave NE, MSC09 5030, Albuquerque, NM, 87131, USAEmail mtohen@salud.unm.e...

Full description

Bibliographic Details
Main Author: Tohen M
Format: Article
Language:English
Published: Dove Medical Press 2021-05-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/cariprazine-as-a-treatment-option-for-depressive-episodes-associated-w-peer-reviewed-fulltext-article-DDDT
id doaj-a85b74b3312345f2bb67bc6296c1ea8b
record_format Article
spelling doaj-a85b74b3312345f2bb67bc6296c1ea8b2021-05-13T19:50:46ZengDove Medical PressDrug Design, Development and Therapy1177-88812021-05-01Volume 152005201264715Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent DataTohen MMauricio Tohen Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, USACorrespondence: Mauricio TohenDepartment of Psychiatry and Behavioral Sciences, University of New Mexico, 2400 Tucker Ave NE, MSC09 5030, Albuquerque, NM, 87131, USAEmail mtohen@salud.unm.eduAbstract: Depressive episodes, the most frequent episodes in bipolar disorder, contribute in large part to poor functional outcomes. Very few treatments, however, have been approved by the Food and Drug Administration for the treatment of bipolar depression. Cariprazine, a broad-spectrum dopamine antagonist/partial agonist with dopamine D3/D2 (preferring D3) and serotonin 5-HT1A receptor partial agonist properties, was recently approved. A review of the literature suggests that it is an effective and well-tolerated treatment for bipolar depression.Keywords: Cariprazine, bipolar depression, antipsychotics, psychopharmacologyhttps://www.dovepress.com/cariprazine-as-a-treatment-option-for-depressive-episodes-associated-w-peer-reviewed-fulltext-article-DDDTcariprazinebipolar depressionantipsychoticspsychopharmacology
collection DOAJ
language English
format Article
sources DOAJ
author Tohen M
spellingShingle Tohen M
Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
Drug Design, Development and Therapy
cariprazine
bipolar depression
antipsychotics
psychopharmacology
author_facet Tohen M
author_sort Tohen M
title Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
title_short Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
title_full Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
title_fullStr Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
title_full_unstemmed Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
title_sort cariprazine as a treatment option for depressive episodes associated with bipolar 1 disorder in adults: an evidence-based review of recent data
publisher Dove Medical Press
series Drug Design, Development and Therapy
issn 1177-8881
publishDate 2021-05-01
description Mauricio Tohen Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, USACorrespondence: Mauricio TohenDepartment of Psychiatry and Behavioral Sciences, University of New Mexico, 2400 Tucker Ave NE, MSC09 5030, Albuquerque, NM, 87131, USAEmail mtohen@salud.unm.eduAbstract: Depressive episodes, the most frequent episodes in bipolar disorder, contribute in large part to poor functional outcomes. Very few treatments, however, have been approved by the Food and Drug Administration for the treatment of bipolar depression. Cariprazine, a broad-spectrum dopamine antagonist/partial agonist with dopamine D3/D2 (preferring D3) and serotonin 5-HT1A receptor partial agonist properties, was recently approved. A review of the literature suggests that it is an effective and well-tolerated treatment for bipolar depression.Keywords: Cariprazine, bipolar depression, antipsychotics, psychopharmacology
topic cariprazine
bipolar depression
antipsychotics
psychopharmacology
url https://www.dovepress.com/cariprazine-as-a-treatment-option-for-depressive-episodes-associated-w-peer-reviewed-fulltext-article-DDDT
work_keys_str_mv AT tohenm cariprazineasatreatmentoptionfordepressiveepisodesassociatedwithbipolar1disorderinadultsanevidencebasedreviewofrecentdata
_version_ 1721441899401707520